KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Inventory (2017 - 2025)

Historic Inventory for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $614.5 million.

  • Amneal Pharmaceuticals' Inventory rose 304.2% to $614.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $614.5 million, marking a year-over-year increase of 304.2%. This contributed to the annual value of $612.5 million for FY2024, which is 534.41% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Inventory is $614.5 million, which was up 304.2% from $609.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Inventory registered a high of $614.5 million during Q3 2025, and its lowest value of $489.4 million during Q4 2021.
  • In the last 5 years, Amneal Pharmaceuticals' Inventory had a median value of $550.6 million in 2023 and averaged $556.2 million.
  • The largest annual percentage gain for Amneal Pharmaceuticals' Inventory in the last 5 years was 1789.12% (2021), contrasted with its biggest fall of 25.68% (2021).
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Inventory stood at $489.4 million in 2021, then increased by 8.45% to $530.7 million in 2022, then rose by 9.54% to $581.4 million in 2023, then increased by 5.34% to $612.5 million in 2024, then increased by 0.33% to $614.5 million in 2025.
  • Its last three reported values are $614.5 million in Q3 2025, $609.0 million for Q2 2025, and $601.4 million during Q1 2025.